Arcus Biosciences (RCUS) Net Income towards Common Stockholders (2017 - 2026)

Arcus Biosciences' Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$128.0 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 14.29% year-over-year to -$128.0 million in Q1 2026; TTM through Mar 2026 was -$369.0 million, a 5.63% increase from a year earlier, with the FY2025 full-year figure at -$353.0 million, down 24.73% from the prior year.
• Net Income towards Common Stockholders declined to -$128.0 million in Q1 2026 per RCUS's latest filing, from -$106.0 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$4.0 million in Q1 2024 and bottomed at -$135.0 million in Q3 2025.
• The 5-year median for Net Income towards Common Stockholders is -$80.5 million (2023), against an average of -$83.6 million.
• Across the five-year window, Net Income towards Common Stockholders soared 95.0% in 2024 and sank 2700.0% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$67.0 million in 2022, then declined by 20.9% to -$81.0 million in 2023, then slipped by 16.05% to -$94.0 million in 2024, then declined by 12.77% to -$106.0 million in 2025, then dropped by 20.75% to -$128.0 million in 2026.
• Per Business Quant, the three latest RCUS Net Income towards Common Stockholders figures stand at -$128.0 million (Q1 2026), -$106.0 million (Q4 2025), and -$135.0 million (Q3 2025).